Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.68 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862211 | 1.00 | CRBN (0.68) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18438844 | 0.92 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL17859027 | 0.92 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL17873788 | 0.92 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22276654 | 0.92 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20294798 | 0.91 | CRBN (0.75) | CRBNDDB1IKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL31477809 | 0.91 | CRBN (0.78) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20294800 | 0.91 | CRBN (0.75) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23124803 | 0.90 | CRBN (0.76) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22150447 | 0.90 | CRBN (0.76) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885IKZF3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.